Takeda Pharmaceutical Company Limited (TAK)
USD 13.11
(-1.87%)
USD 13.11
(-1.87%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | 214.07 Billion JPY | -56.36% |
| 2023 | 490.5 Billion JPY | 6.44% |
| 2022 | 460.84 Billion JPY | -9.51% |
| 2021 | 509.26 Billion JPY | 407.2% |
| 2020 | 100.4 Billion JPY | -51.01% |
| 2019 | 204.96 Billion JPY | -15.23% |
| 2018 | 241.78 Billion JPY | 55.13% |
| 2017 | 155.86 Billion JPY | 19.14% |
| 2016 | 130.82 Billion JPY | 201.22% |
| 2015 | -129.25 Billion JPY | -192.81% |
| 2014 | 139.27 Billion JPY | 13.69% |
| 2013 | 122.5 Billion JPY | -53.78% |
| 2012 | 265.02 Billion JPY | -27.8% |
| 2011 | 367.08 Billion JPY | -12.64% |
| 2010 | 420.21 Billion JPY | 37.11% |
| 2009 | 306.46 Billion JPY | -27.57% |
| 2008 | 423.12 Billion JPY | -7.72% |
| 2007 | 458.5 Billion JPY | 13.83% |
| 2006 | 402.8 Billion JPY | 4.55% |
| 2005 | 385.27 Billion JPY | 3.67% |
| 2004 | 371.63 Billion JPY | 19.62% |
| 2003 | 310.68 Billion JPY | 10.47% |
| 2002 | 281.24 Billion JPY | 24.39% |
| 2001 | 226.1 Billion JPY | 31.88% |
| 2000 | 171.44 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 168.57 Billion JPY | 41044.57% |
| 2024 Q3 | 104.91 Billion JPY | 312.63% |
| 2024 FY | 526.51 Billion JPY | 7.34% |
| 2024 Q4 | 187.27 Billion JPY | 78.51% |
| 2024 Q2 | -49.34 Billion JPY | -16.14% |
| 2023 Q1 | 210.94 Billion JPY | 780.92% |
| 2023 Q3 | 146.99 Billion JPY | 40.74% |
| 2023 FY | 490.5 Billion JPY | 6.44% |
| 2023 Q4 | 88.56 Billion JPY | -39.75% |
| 2023 Q2 | 104.43 Billion JPY | -50.49% |
| 2022 FY | 460.84 Billion JPY | -9.51% |
| 2022 Q3 | 116.48 Billion JPY | 19.56% |
| 2022 Q1 | 248.55 Billion JPY | 65.11% |
| 2022 Q4 | -30.97 Billion JPY | -126.6% |
| 2022 Q2 | 97.42 Billion JPY | -60.8% |
| 2021 Q2 | 48.3 Billion JPY | -71.13% |
| 2021 Q3 | 143.14 Billion JPY | 196.34% |
| 2021 Q4 | 150.54 Billion JPY | 5.17% |
| 2021 FY | 509.26 Billion JPY | 407.2% |
| 2021 Q1 | 167.28 Billion JPY | 369.22% |
| 2020 Q1 | 9.86 Billion JPY | 112.42% |
| 2020 Q3 | 53.51 Billion JPY | 32.31% |
| 2020 Q4 | -62.13 Billion JPY | -216.12% |
| 2020 FY | 100.4 Billion JPY | -51.01% |
| 2020 Q2 | 40.44 Billion JPY | 309.93% |
| 2019 Q3 | 112.46 Billion JPY | 53.88% |
| 2019 Q4 | -79.45 Billion JPY | -170.65% |
| 2019 FY | 204.96 Billion JPY | -15.23% |
| 2019 Q2 | 73.08 Billion JPY | -26.08% |
| 2019 Q1 | 98.87 Billion JPY | 222.82% |
| 2018 Q2 | 39.37 Billion JPY | -79.81% |
| 2018 FY | 241.78 Billion JPY | 55.13% |
| 2018 Q4 | -80.49 Billion JPY | -191.54% |
| 2018 Q3 | 87.93 Billion JPY | 123.34% |
| 2018 Q1 | 194.97 Billion JPY | 416.71% |
| 2017 Q1 | 152.93 Billion JPY | 517.26% |
| 2017 FY | 155.86 Billion JPY | 19.14% |
| 2017 Q4 | -61.56 Billion JPY | -211.22% |
| 2017 Q3 | 55.35 Billion JPY | 505.42% |
| 2017 Q2 | 9.14 Billion JPY | -94.02% |
| 2016 Q1 | 49.55 Billion JPY | 115.1% |
| 2016 FY | 130.82 Billion JPY | 201.22% |
| 2016 Q3 | 57.03 Billion JPY | -6.34% |
| 2016 Q2 | 60.89 Billion JPY | 22.86% |
| 2016 Q4 | -36.65 Billion JPY | -164.27% |
| 2015 Q3 | 82.35 Billion JPY | 55.37% |
| 2015 FY | -129.25 Billion JPY | -192.81% |
| 2015 Q4 | -328.3 Billion JPY | -498.64% |
| 2015 Q2 | 53 Billion JPY | -16.77% |
| 2015 Q1 | 63.68 Billion JPY | 311.71% |
| 2014 Q2 | 52.7 Billion JPY | 10.48% |
| 2014 Q3 | 66.78 Billion JPY | 26.73% |
| 2014 Q4 | -30.08 Billion JPY | -145.04% |
| 2014 FY | 139.27 Billion JPY | 13.69% |
| 2014 Q1 | 47.7 Billion JPY | 269.36% |
| 2013 Q4 | -28.16 Billion JPY | 89.39% |
| 2013 FY | 122.5 Billion JPY | -53.78% |
| 2013 Q1 | 216.1 Billion JPY | 158.75% |
| 2013 Q2 | 200.09 Billion JPY | -7.41% |
| 2013 Q3 | -265.52 Billion JPY | -232.7% |
| 2012 Q1 | 220.6 Billion JPY | 176.24% |
| 2012 Q4 | -367.82 Billion JPY | -276.06% |
| 2012 Q3 | 208.91 Billion JPY | 2.75% |
| 2012 Q2 | 203.33 Billion JPY | -7.83% |
| 2012 FY | 265.02 Billion JPY | -27.8% |
| 2011 Q4 | -289.34 Billion JPY | -233.23% |
| 2011 Q1 | 219.48 Billion JPY | 177.33% |
| 2011 Q2 | 219.76 Billion JPY | 0.13% |
| 2011 Q3 | 217.18 Billion JPY | -1.17% |
| 2011 FY | 367.08 Billion JPY | -12.64% |
| 2010 FY | 420.21 Billion JPY | 37.11% |
| 2010 Q3 | 224.54 Billion JPY | -5.14% |
| 2010 Q2 | 236.71 Billion JPY | -2.49% |
| 2010 Q4 | -283.82 Billion JPY | -226.4% |
| 2010 Q1 | 242.77 Billion JPY | 181.63% |
| 2009 Q4 | -297.42 Billion JPY | -210.76% |
| 2009 FY | 306.46 Billion JPY | -27.57% |
| 2009 Q2 | 251.94 Billion JPY | 0.0% |
| 2009 Q3 | 268.52 Billion JPY | 6.58% |
| 2008 FY | 423.12 Billion JPY | -7.72% |
| 2007 FY | 458.5 Billion JPY | 13.83% |
| 2006 FY | 402.8 Billion JPY | 4.55% |
| 2005 FY | 385.27 Billion JPY | 3.67% |
| 2004 FY | 371.63 Billion JPY | 19.62% |
| 2003 FY | 310.68 Billion JPY | 10.47% |
| 2002 FY | 281.24 Billion JPY | 24.39% |
| 2001 FY | 226.1 Billion JPY | 31.88% |
| 2000 FY | 171.44 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 204.37 Million USD | -104646.69% |
| Bausch Health Companies Inc. | 963 Million USD | -22130.01% |
| Catalent, Inc. | -749 Million USD | 28681.442% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 29570.677% |
| Elanco Animal Health Incorporated | 326 Million USD | -65567.178% |
| Perrigo Company plc | 151.9 Million USD | -140831.534% |
| Teva Pharmaceutical Industries Limited | 433 Million USD | -49339.954% |
| Zoetis Inc. | 3.06 Billion USD | -6875.399% |